The Department of Hepatology, Gastroenterology and Infectious Diseases, Qina Faculty of Medicine, South Valley University* and Qina Fever Hospital, Ministry of Health**, Qina City, Egypt
Abstract Background: The highest prevalence of chronic Hepatitis C Virus (HCV) was reported in Egypt. DAAs has been avail-able, with a reported 12 weeks sustained virologic response (12w-SVR) above 95% after treatment for 12 weaks. Aim of Study: Aim of the current study was to evaluate evaluate efficacy of the 2-DAAs combination of ombitasvir, paritaprevir (co-dosed with ritonavir) with ribavirin in treatment of chronic HCV patients and evaluate correlation between virologic failure and risk factors. Patients and Methods: Chronic HCV patients (n=100) were enrolled in the current study. All patients received 25mg ombitasvir, 150mg paritaprevir, and 100mg ritonavir orally once daily plus Ribavirin 600-1000mg) for 12 weaks. Response was assessed 12 weeks after end of treatment by SRT-PCR. Results: The interferon-free regimen of ombitasvir/ pari-taprevir/ritonavir + ribavirin for 12 weeks achieved sustained virologic response in 91% of patients. Conclusion: In conclusion, the 12-week 2-DAA regimen of OBV/PTV/r and DSV achieved an SVR12 rate of 91% in previously untreated patients with HCV infection. Liver Cirrhosis has negative impact on 12 weeks-SVR. Conflict of Interest: The authors have no conflict of interest related to this publication.
SHAMARDAN E.S. BAZEED, M.D., H. S. M. M., & S. MOHAMED, M.Sc., M. (2020). Efficacy and Safety of Omibtasvir, Paritaprevir and Ritonavir Combination with Ribavirin for Treatment of Chronic Hepatitis C Patients. The Medical Journal of Cairo University, 88(March), 573-575. doi: 10.21608/mjcu.2020.104608
MLA
HASAN S. MAHMOUD, M.D.; SHAMARDAN E.S. BAZEED, M.D.; MOHAMED S. MOHAMED, M.Sc.. "Efficacy and Safety of Omibtasvir, Paritaprevir and Ritonavir Combination with Ribavirin for Treatment of Chronic Hepatitis C Patients". The Medical Journal of Cairo University, 88, March, 2020, 573-575. doi: 10.21608/mjcu.2020.104608
HARVARD
SHAMARDAN E.S. BAZEED, M.D., H. S. M. M., S. MOHAMED, M.Sc., M. (2020). 'Efficacy and Safety of Omibtasvir, Paritaprevir and Ritonavir Combination with Ribavirin for Treatment of Chronic Hepatitis C Patients', The Medical Journal of Cairo University, 88(March), pp. 573-575. doi: 10.21608/mjcu.2020.104608
VANCOUVER
SHAMARDAN E.S. BAZEED, M.D., H. S. M. M., S. MOHAMED, M.Sc., M. Efficacy and Safety of Omibtasvir, Paritaprevir and Ritonavir Combination with Ribavirin for Treatment of Chronic Hepatitis C Patients. The Medical Journal of Cairo University, 2020; 88(March): 573-575. doi: 10.21608/mjcu.2020.104608